Abstracts tagged "collagen and systemic sclerosis"

Abstract Number: 740 • 2017 ACR/ARHP Annual Meeting
Prediction of Fibrosis Progression in Systemic Sclerosis By Collagen Biomarkers
Rucsandra Dobrota¹, Suzana Jordan², Pernille Juhl³, Britta Maurer⁴, Lukas Wildi⁴, Anne-C. Bay-Jensen⁵, Morten Karsdal⁶, Anne Sofie Siebuhr⁷ and Oliver Distler², ¹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Nordic Bioscience, Herlev, Denmark, ⁴Department of Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark, ⁶Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ⁷Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, Herlev, Denmark
Background/Purpose: Altered extracellular matrix (ECM) remodeling leading to fibrosis is a key pathogenic process in systemic sclerosis (SSc). We previously showed that collagen formation and…
Abstract Number: 771 • 2017 ACR/ARHP Annual Meeting
Serological Biomarkers of Collagen Formation Is Increased in Systemic Sclerosis
Pernille Juhl¹, Mette Mogensen², Line Iversen², Tonny Karlsmark², Morten Karsdal³, Anne-C. Bay-Jensen⁴ and Anne Sofie Siebuhr⁵, ¹Nordic Bioscience, Herlev, Denmark, ²Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ³Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ⁴Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark, ⁵Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, Herlev, Denmark
Background/Purpose: Systemic sclerosis (SSc) is a multisystem, autoimmune disease characterized by immune dysregulation, vasculopathy and excessive fibrosis of the skin and internal organs. Fibrosis is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].